About vaccinex inc - VCNX
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in1997 and is headquartered in Rochester, NY.
VCNX At a Glance
Vaccinex, Inc.
1895 Mount Hope Avenue
Rochester, New York 14620
| Phone | 1-585-271-2700 | Revenue | 2.10M | |
| Industry | Biotechnology | Net Income | -5,260,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 248.586% | |
| Fiscal Year-end | 12 / 2026 | Employees | N/A | |
| View SEC Filings |
VCNX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.374 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.937 |
| Enterprise Value to Sales | 4.804 |
| Total Debt to Enterprise Value | 0.548 |
VCNX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 1.814 |
| Total Asset Turnover | 0.953 |
VCNX Liquidity
| Current Ratio | 0.454 |
| Quick Ratio | 0.454 |
| Cash Ratio | 0.036 |
VCNX Profitability
| Gross Margin | 98.329 |
| Operating Margin | -249.737 |
| Pretax Margin | -251.074 |
| Net Margin | -251.074 |
| Return on Assets | -239.363 |
| Return on Equity | N/A |
| Return on Total Capital | 253.616 |
| Return on Invested Capital | N/A |
VCNX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -266.008 |
| Total Debt to Total Assets | 306.67 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -266.008 |